Benign Prostatic Hyperplasia: Global Market Analysis of Treatments & Disease Management Implications

Published by: PJB Publications USA Inc.

Published: Jun. 29, 2002 - 173 Pages

Table of Contents

1.1 Scope and Objectives of Report   

1.2 Methodology   

1.2.1 Overview   

1.2.2 Population Projections   

1.2.3 Sales Projections   

1.2.4 Compound Annual Growth Rate (CAGR)   

1.3 Market Overview and Summary   

1.3.1 BPH Treatment Overview   

1.3.2 BPH Prevalence   

1.3.3 BPH Market Size and Projections   

1.3.4 BPH Drug Market Leaders   

1.3.5 Factors Impacting Future Drug Sales   

1.3.6 Market Trends and Opportunities   

2  Overview of BPH   

2.1 Definition of BPH   

2.2 Normal Physiology   

2.3 Pathophysiology of BPH   

2.3.1 Hormonal Influences   

2.4 BPH Symptoms   

2.5 Epidemiology and Risk Factors   

2.6 Complications of BPH   

2.7 Comorbidities in Patients with BPH   

2.7.1 Prostatitis   

2.7.2 Prostate Cancer   

2.7.3 Renal Insufficiency   

2.8 Prevalence and Incidence   

2.8.1 Global Prevalence of BPH With LUTS   

2.8.2 Variances in BPH Prevalence With LUTS by Country   

2.9 Impact of BPH on Quality of Life   

2.10 Treatment Utilization and Costs: Surgery and Pharmaceuticals   

2.10.1 Surgery Utilization in the U.S.   

2.10.2 Surgery Utilization in Western Europe   

2.10.3 Pharmaceutical Treatment Utilization in the U.S.   

2.10.4 Pharmaceutical Treatment Utilization in Western Europe   

2.10.5 Pharmaceutical Treatment Utilization in Japan   

2.11 Primary Care Physician Versus Urology Specialist Medical Care Trends   

3  BPH Assessment, Treatment, and Management   

3.1 Patient Assessment Methods   

3.1.1 Physical Examination Parameters   

3.1.2 Diagnostic Tests   

3.1.3 Survey Instruments for Classifying BPH Severity   

3.1.4 AUA Symptom Index   

3.1.5 Madsen-Iversen Scoring System   

3.1.6 Boyarsky System   

3.1.7 Strengths and Weaknesses of Symptom Instruments   

3.1.8 Recommended Symptom Index Instrument (U.S.)   

3.2 BPH Therapy: Options, Benefits, and Goals   

3.3 Watchful Waiting Approach   

3.4 Prescription Drug Treatments   

3.4.1 Overview of Major Drug Classes   

3.4.2 Tamsulosin (Flomax, Harnal, Omnic)   

3.4.3 Doxazosin (Cardura)   

3.4.4 Terazosin (Hytrin)   

3.4.5 Alfuzosin (UroXatral, Xatral)   

3.4.6 Finasteride (Proscar)   

3.4.7 Combination Drug Therapy   

3.5 Phytotherapies   

3.5.1 Saw Palmetto Berry Extract (Serenoa repens)   

3.5.2 African plum bark (Pygeum africanum): Tadenan, Prostata   

3.5.3 Beta-Sitosterol/South African Star Grass (Hypoxis rooperi)   

3.5.4 Questionable Herbal Agents   

3.6 Surgical/Invasive Procedures   

3.6.1 TURP/TUIP   

3.6.2 Transurethral Needle Ablation (TUNA)   

3.6.3 Transurethral Microwave Thermotherapy (TUMT)   

3.6.4 Laser Prostatectomy   

3.6.5 Balloon Dilation   

3.6.6 Electrical Vaporization   

3.7 Evaluation of Treatment   

3.7.1 Symptom Improvement Based on Current Treatment Modalities   

3.7.2 Patient Treatment Preferences in Informed Decision Making   

4  BPH Treatments in Development   

4.1 Drugs in Development   

4.2 Dutasteride   

4.3 Hormonal Drug Influences: 5-Alpha Reductase Inhibitors   

4.4 BPH and Male Pattern Baldness   

4.5 Technology Advances for Future Drug Modeling   

4.5.1 Stem Cell Therapy   

4.5.2 Gene Therapy   

4.5.3 BPH Gene Expression   

5  Market Analysis   

5.1 Overview of Total Global Pharma Market   

5.2 BPH Market Sizes and Projections   

5.2.1 United States   

5.2.2 Europe   

5.2.3 Japan   

5.2.4 Rest of World   

5.3 BPH Competitive Drug Analysis   

5.3.1 Tamsulosin (Flomax, Harnal, Omnic, Pradif)   

5.3.2 Finasteride (Proscar)   

5.3.3 Doxazosin (Cardura)   

5.3.4 Terazosin (Hytrin)   

5.3.5 Alfuzosin (Xatral, UroXatral)   

6  Market Trends and Opportunities for Companies Serving the Urological Market   

6.1 Where is the Urologic Market Heading?   

6.2 Healthcare Spending and Benefit Design   

6.2.1 Defined Contribution (DC) Models   

6.2.2 Defined Contribution and Implications for Pharma Companies   

6.2.3 Other Healthcare Players Entering the Market   

6.3 The Disease Management (DM) Industry   

6.3.1 A Look at DM   

6.3.2 Definition of Disease Management   

6.3.3 Disease Management and HMOs   

6.3.4 Disease Management and Defined Contribution   

6.4 Direct-to-Consumer (DTC) Advertising   

6.4.1 U.S. Issues: DTC Advertising Pros and Cons   

6.4.2 What Consumers Say About DTC Advertising   

6.4.3 DTC Advertising and Impact on Urologic Drug Sales   

6.4.4 DTC Advertising in Europe?   

6.5 BPH Clinical Trial Directives   

7  Company Profiles   

7.1 Abbott Laboratories   

7.2 ALZA Corp./Johnson & Johnson/Ortho-McNeil   

7.3 Boehringer Ingelheim Pharmaceuticals, Inc.   

7.4 Merck & Co., Inc.   

7.5 Pfizer, Inc.   

7.6 Pharmacia Corp.   

7.7 Sanofi-Synthelabo   

7.8 Schwarz Pharma AG   

7.9 Yamanouchi Pharmaceuticals Co., Ltd.   

8  Company Directory   

9  References   

List of Tables

Table 2-1  Comparative PSA Values for BPH and Prostate Cancer   

Table 2-2  Ability of PSA to Distinguish Prostate Cancer From BPH   

Table 2-3  Prevalence of BPH With LUTS by Country   

Table 2-4  Prostectomies/1,000 Men Aged 55 or Older  by Country   

Table 3-1  AUA Symptom Index Instrument (Lower Urinary Tract Symptoms)   

Table 3-2  Median Probability of BPH Symptom Improvement Based on Treatment Modality   

Table 4-1  Drugs in Development for BPH and LUTS   

Table 5-1  Total Global Pharmaceuticals Market Size by Geographic Region 2002   

Table 5-2  Total Global Pharmaceuticals Market Share by Geographic Region 2002   

Table 5-3  World BPH Market Size and Growth 2000-2006   

Table 5-4  U.S. BPH Market Size and Growth 2000-2006   

Table 5-5  European* BPH Market Size and Growth 2000-2006   

Table 5-6  Japanese BPH Market Size and Growth 2000-2006   

Table 5-7  Rest of World BPH Market Size and Growth 2000-2006   

Table 5-8  BPH Drug Revenues 2000-2001   

Table 5-9  Tamsulosin Drug Revenues 2000-2001   

Table 5-10  Non-Tamsulosin Drug Revenues 2000-2001   

Table 6-1  Percentage of HMOs Implementing DM Programs by Specific Disease 1999   

Table 6-2  Defined Contribution and the Evolving Disease Management Model   

Table 6-3  Top Ranking Urologic Products and Sales

(Based on Top 50 Drugs for DTC Advertisement Spending)   

List of Figures

Figure 2-1  Male Urethra, Prostate, and Normal Urine Flow   

Figure 2-2  Urine Flow With BPH   

Figure 2-3  Estimated BPH Prevalence, Age 50 and Over by Geographic Region   

Figure 3-1  Treatment Preferences of Informed BPH Patients   

Figure 5-1  Total Global Pharmaceuticals Market Size by Geographic Region 2002   

Figure 5-2  Total Global Pharmaceuticals Market Share by Geographic Region 2002   

Figure 5-3  World BPH Market Size 2000-2006   

Figure 5-4  World BPH Market Size by Geographic Region 2000-2006   

Figure 5-5  World BPH Market Growth (CAGRs) by Geographic Region

2000-2001, 2001-2005, 2000-2006   

Figure 5-6  U.S. BPH Market Size 2000-2006   

Figure 5-7  European* BPH Market Size 2000-2006   

Figure 5-8  Japanese BPH Market Size 2000-2006   

Figure 5-9  Rest of World BPH Market Size 2000-2006   

Figure 5-10  BPH Drug Revenues 2000-2001   

Figure 5-11  Tamsulosin Drug Revenues 2000-2001   

Figure 5-12  Non-Tamsulosin Drug Revenues 2000-2001   

Abstract

Benign Prostatic Hyperplasia: Global Market Analysis of Treatments & Disease Management Implications thoroughly analyzes the forces driving and affecting the market for these treatments, answering several burning questions, including:

• What treatments are in development for BPH? Who is developing them? When will they reach market? What is their commercial future?
• How will DTC advertising impact drug sales, patient compliance, and disease management?
• How are the policies of disease management companies and health insurers influencing market dynamics?

Based on data collected from interviews with senior managers, as well as other primary sources, Benign Prostatic Hyperplasia analyzes incidence and demographics to help define market potential, and scrutinizes other forces and dynamics to predict the shape of this market for years to come.

Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.